カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界の麻疹・風疹（MR）ワクチン市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Measles and Rubella (MR) Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19746）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19746
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：71
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界の麻疹・風疹（MR）ワクチン市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

麻疹・風疹（MR）ワクチン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界の麻疹・風疹（MR）ワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

麻疹・風疹（MR）ワクチン市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・MRワクチン、MRBEVワクチン

用途別セグメントは次のように区分されます。
・民間流通経路、公共流通経路

世界の麻疹・風疹（MR）ワクチン市場の主要な市場プレーヤーは以下のとおりです。
・PT Bio Farma、Bio-Manguinhos、BE Vaccines、Crucell Switzerland AG

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、麻疹・風疹（MR）ワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要な麻疹・風疹（MR）ワクチンメーカーの企業概要、2019年～2022年までの麻疹・風疹（MR）ワクチンの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要な麻疹・風疹（MR）ワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別麻疹・風疹（MR）ワクチンの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までの麻疹・風疹（MR）ワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域での麻疹・風疹（MR）ワクチン市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、および麻疹・風疹（MR）ワクチンの産業チェーンを掲載しています。
・第13、14、15章では、麻疹・風疹（MR）ワクチンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- 麻疹・風疹（MR）ワクチンの概要
- 種類別分析（2017年vs2021年vs2028年）：MRワクチン、MRBEVワクチン
- 用途別分析（2017年vs2021年vs2028年）：民間流通経路、公共流通経路
- 世界の麻疹・風疹（MR）ワクチン市場規模・予測
- 世界の麻疹・風疹（MR）ワクチン生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- PT Bio Farma、Bio-Manguinhos、BE Vaccines、Crucell Switzerland AG
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：MRワクチン、MRBEVワクチン
・用途別分析2017年-2028年：民間流通経路、公共流通経路
・麻疹・風疹（MR）ワクチンの北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・麻疹・風疹（MR）ワクチンのヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・麻疹・風疹（MR）ワクチンのアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・麻疹・風疹（MR）ワクチンの南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・麻疹・風疹（MR）ワクチンの中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Measles and Rubella (MR) Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Measles and Rubella (MR) Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during forecast period 2022-2028. Private Distribution Channel accounting for % of the Measles and Rubella (MR) Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While MR Vaccine segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Measles and Rubella (MR) Vaccine include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Crucell Switzerland AG, and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Measles and Rubella (MR) Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
MR Vaccine
MRBEV Vaccine
Market segment by Application can be divided into
Private Distribution Channel
Public Distribution Channel
The key market players for global Measles and Rubella (MR) Vaccine market are listed below:
PT Bio Farma
Bio-Manguinhos
BE Vaccines
Crucell Switzerland AG
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Measles and Rubella (MR) Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Measles and Rubella (MR) Vaccine, with price, sales, revenue and global market share of Measles and Rubella (MR) Vaccine from 2019 to 2022.
Chapter 3, the Measles and Rubella (MR) Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Measles and Rubella (MR) Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Measles and Rubella (MR) Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Measles and Rubella (MR) Vaccine.
Chapter 13, 14, and 15, to describe Measles and Rubella (MR) Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Measles and Rubella (MR) Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Measles and Rubella (MR) Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 MR Vaccine
1.2.3 MRBEV Vaccine
1.3 Market Analysis by Application
1.3.1 Overview: Global Measles and Rubella (MR) Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Private Distribution Channel
1.3.3 Public Distribution Channel
1.4 Global Measles and Rubella (MR) Vaccine Market Size & Forecast
1.4.1 Global Measles and Rubella (MR) Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Measles and Rubella (MR) Vaccine Sales in Volume (2017-2028)
1.4.3 Global Measles and Rubella (MR) Vaccine Price (2017-2028)
1.5 Global Measles and Rubella (MR) Vaccine Production Capacity Analysis
1.5.1 Global Measles and Rubella (MR) Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Measles and Rubella (MR) Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Measles and Rubella (MR) Vaccine Market Drivers
1.6.2 Measles and Rubella (MR) Vaccine Market Restraints
1.6.3 Measles and Rubella (MR) Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 PT Bio Farma
2.1.1 PT Bio Farma Details
2.1.2 PT Bio Farma Major Business
2.1.3 PT Bio Farma Measles and Rubella (MR) Vaccine Product and Services
2.1.4 PT Bio Farma Measles and Rubella (MR) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Bio-Manguinhos
2.2.1 Bio-Manguinhos Details
2.2.2 Bio-Manguinhos Major Business
2.2.3 Bio-Manguinhos Measles and Rubella (MR) Vaccine Product and Services
2.2.4 Bio-Manguinhos Measles and Rubella (MR) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3 BE Vaccines
2.3.1 BE Vaccines Details
2.3.2 BE Vaccines Major Business
2.3.3 BE Vaccines Measles and Rubella (MR) Vaccine Product and Services
2.3.4 BE Vaccines Measles and Rubella (MR) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4 Crucell Switzerland AG
2.4.1 Crucell Switzerland AG Details
2.4.2 Crucell Switzerland AG Major Business
2.4.3 Crucell Switzerland AG Measles and Rubella (MR) Vaccine Product and Services
2.4.4 Crucell Switzerland AG Measles and Rubella (MR) Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Measles and Rubella (MR) Vaccine Breakdown Data by Manufacturer
3.1 Global Measles and Rubella (MR) Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Measles and Rubella (MR) Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Measles and Rubella (MR) Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Measles and Rubella (MR) Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Measles and Rubella (MR) Vaccine Manufacturer Market Share in 2021
3.5 Global Measles and Rubella (MR) Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Measles and Rubella (MR) Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Measles and Rubella (MR) Vaccine Market Size by Region
4.1.1 Global Measles and Rubella (MR) Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Measles and Rubella (MR) Vaccine Revenue by Region (2017-2028)
4.2 North America Measles and Rubella (MR) Vaccine Revenue (2017-2028)
4.3 Europe Measles and Rubella (MR) Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Measles and Rubella (MR) Vaccine Revenue (2017-2028)
4.5 South America Measles and Rubella (MR) Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Measles and Rubella (MR) Vaccine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Measles and Rubella (MR) Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Measles and Rubella (MR) Vaccine Revenue by Type (2017-2028)
5.3 Global Measles and Rubella (MR) Vaccine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Measles and Rubella (MR) Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Measles and Rubella (MR) Vaccine Revenue by Application (2017-2028)
6.3 Global Measles and Rubella (MR) Vaccine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
7.2 North America Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
7.3 North America Measles and Rubella (MR) Vaccine Market Size by Country
7.3.1 North America Measles and Rubella (MR) Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Measles and Rubella (MR) Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
8.2 Europe Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
8.3 Europe Measles and Rubella (MR) Vaccine Market Size by Country
8.3.1 Europe Measles and Rubella (MR) Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Measles and Rubella (MR) Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Measles and Rubella (MR) Vaccine Market Size by Region
9.3.1 Asia-Pacific Measles and Rubella (MR) Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Measles and Rubella (MR) Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
10.2 South America Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
10.3 South America Measles and Rubella (MR) Vaccine Market Size by Country
10.3.1 South America Measles and Rubella (MR) Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Measles and Rubella (MR) Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Measles and Rubella (MR) Vaccine Market Size by Country
11.3.1 Middle East & Africa Measles and Rubella (MR) Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Measles and Rubella (MR) Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Measles and Rubella (MR) Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Measles and Rubella (MR) Vaccine
12.3 Measles and Rubella (MR) Vaccine Production Process
12.4 Measles and Rubella (MR) Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Measles and Rubella (MR) Vaccine Typical Distributors
13.3 Measles and Rubella (MR) Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Measles and Rubella (MR) Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Measles and Rubella (MR) Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. PT Bio Farma Basic Information, Manufacturing Base and Competitors
Table 4. PT Bio Farma Major Business
Table 5. PT Bio Farma Measles and Rubella (MR) Vaccine Product and Services
Table 6. PT Bio Farma Measles and Rubella (MR) Vaccine Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Bio-Manguinhos Basic Information, Manufacturing Base and Competitors
Table 8. Bio-Manguinhos Major Business
Table 9. Bio-Manguinhos Measles and Rubella (MR) Vaccine Product and Services
Table 10. Bio-Manguinhos Measles and Rubella (MR) Vaccine Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. BE Vaccines Basic Information, Manufacturing Base and Competitors
Table 12. BE Vaccines Major Business
Table 13. BE Vaccines Measles and Rubella (MR) Vaccine Product and Services
Table 14. BE Vaccines Measles and Rubella (MR) Vaccine Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 15. Crucell Switzerland AG Basic Information, Manufacturing Base and Competitors
Table 16. Crucell Switzerland AG Major Business
Table 17. Crucell Switzerland AG Measles and Rubella (MR) Vaccine Product and Services
Table 18. Crucell Switzerland AG Measles and Rubella (MR) Vaccine Sales (Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 19. Global Measles and Rubella (MR) Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (Units)
Table 20. Global Measles and Rubella (MR) Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 21. Market Position of Manufacturers in Measles and Rubella (MR) Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 22. Global Measles and Rubella (MR) Vaccine Production Capacity by Company, (Units): 2020 VS 2021
Table 23. Head Office and Measles and Rubella (MR) Vaccine Production Site of Key Manufacturer
Table 24. Measles and Rubella (MR) Vaccine New Entrant and Capacity Expansion Plans
Table 25. Measles and Rubella (MR) Vaccine Mergers & Acquisitions in the Past Five Years
Table 26. Global Measles and Rubella (MR) Vaccine Sales by Region (2017-2022) & (Units)
Table 27. Global Measles and Rubella (MR) Vaccine Sales by Region (2023-2028) & (Units)
Table 28. Global Measles and Rubella (MR) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 29. Global Measles and Rubella (MR) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 30. Global Measles and Rubella (MR) Vaccine Sales by Type (2017-2022) & (Units)
Table 31. Global Measles and Rubella (MR) Vaccine Sales by Type (2023-2028) & (Units)
Table 32. Global Measles and Rubella (MR) Vaccine Revenue by Type (2017-2022) & (USD Million)
Table 33. Global Measles and Rubella (MR) Vaccine Revenue by Type (2023-2028) & (USD Million)
Table 34. Global Measles and Rubella (MR) Vaccine Price by Type (2017-2022) & (US$/Unit)
Table 35. Global Measles and Rubella (MR) Vaccine Price by Type (2023-2028) & (US$/Unit)
Table 36. Global Measles and Rubella (MR) Vaccine Sales by Application (2017-2022) & (Units)
Table 37. Global Measles and Rubella (MR) Vaccine Sales by Application (2023-2028) & (Units)
Table 38. Global Measles and Rubella (MR) Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 39. Global Measles and Rubella (MR) Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 40. Global Measles and Rubella (MR) Vaccine Price by Application (2017-2022) & (US$/Unit)
Table 41. Global Measles and Rubella (MR) Vaccine Price by Application (2023-2028) & (US$/Unit)
Table 42. North America Measles and Rubella (MR) Vaccine Sales by Country (2017-2022) & (Units)
Table 43. North America Measles and Rubella (MR) Vaccine Sales by Country (2023-2028) & (Units)
Table 44. North America Measles and Rubella (MR) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 45. North America Measles and Rubella (MR) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 46. North America Measles and Rubella (MR) Vaccine Sales by Type (2017-2022) & (Units)
Table 47. North America Measles and Rubella (MR) Vaccine Sales by Type (2023-2028) & (Units)
Table 48. North America Measles and Rubella (MR) Vaccine Sales by Application (2017-2022) & (Units)
Table 49. North America Measles and Rubella (MR) Vaccine Sales by Application (2023-2028) & (Units)
Table 50. Europe Measles and Rubella (MR) Vaccine Sales by Country (2017-2022) & (Units)
Table 51. Europe Measles and Rubella (MR) Vaccine Sales by Country (2023-2028) & (Units)
Table 52. Europe Measles and Rubella (MR) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 53. Europe Measles and Rubella (MR) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 54. Europe Measles and Rubella (MR) Vaccine Sales by Type (2017-2022) & (Units)
Table 55. Europe Measles and Rubella (MR) Vaccine Sales by Type (2023-2028) & (Units)
Table 56. Europe Measles and Rubella (MR) Vaccine Sales by Application (2017-2022) & (Units)
Table 57. Europe Measles and Rubella (MR) Vaccine Sales by Application (2023-2028) & (Units)
Table 58. Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Region (2017-2022) & (Units)
Table 59. Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Region (2023-2028) & (Units)
Table 60. Asia-Pacific Measles and Rubella (MR) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 61. Asia-Pacific Measles and Rubella (MR) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 62. Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Type (2017-2022) & (Units)
Table 63. Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Type (2023-2028) & (Units)
Table 64. Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Application (2017-2022) & (Units)
Table 65. Asia-Pacific Measles and Rubella (MR) Vaccine Sales by Application (2023-2028) & (Units)
Table 66. South America Measles and Rubella (MR) Vaccine Sales by Country (2017-2022) & (Units)
Table 67. South America Measles and Rubella (MR) Vaccine Sales by Country (2023-2028) & (Units)
Table 68. South America Measles and Rubella (MR) Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 69. South America Measles and Rubella (MR) Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 70. South America Measles and Rubella (MR) Vaccine Sales by Type (2017-2022) & (Units)
Table 71. South America Measles and Rubella (MR) Vaccine Sales by Type (2023-2028) & (Units)
Table 72. South America Measles and Rubella (MR) Vaccine Sales by Application (2017-2022) & (Units)
Table 73. South America Measles and Rubella (MR) Vaccine Sales by Application (2023-2028) & (Units)
Table 74. Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Region (2017-2022) & (Units)
Table 75. Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Region (2023-2028) & (Units)
Table 76. Middle East & Africa Measles and Rubella (MR) Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 77. Middle East & Africa Measles and Rubella (MR) Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 78. Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Type (2017-2022) & (Units)
Table 79. Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Type (2023-2028) & (Units)
Table 80. Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Application (2017-2022) & (Units)
Table 81. Middle East & Africa Measles and Rubella (MR) Vaccine Sales by Application (2023-2028) & (Units)
Table 82. Measles and Rubella (MR) Vaccine Raw Material
Table 83. Key Manufacturers of Measles and Rubella (MR) Vaccine Raw Materials
Table 84. Direct Channel Pros & Cons
Table 85. Indirect Channel Pros & Cons
Table 86. Measles and Rubella (MR) Vaccine Typical Distributors
Table 87. Measles and Rubella (MR) Vaccine Typical Customers
List of Figures
Figure 1. Measles and Rubella (MR) Vaccine Picture
Figure 2. Global Measles and Rubella (MR) Vaccine Revenue Market Share by Type in 2021
Figure 3. MR Vaccine
Figure 4. MRBEV Vaccine
Figure 5. Global Measles and Rubella (MR) Vaccine Revenue Market Share by Application in 2021
Figure 6. Private Distribution Channel
Figure 7. Public Distribution Channel
Figure 8. Global Measles and Rubella (MR) Vaccine Revenue, (USD Million) & (Units): 2017 & 2021 & 2028
Figure 9. Global Measles and Rubella (MR) Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Measles and Rubella (MR) Vaccine Sales (2017-2028) & (Units)
Figure 11. Global Measles and Rubella (MR) Vaccine Price (2017-2028) & (US$/Unit)
Figure 12. Global Measles and Rubella (MR) Vaccine Production Capacity (2017-2028) & (Units)
Figure 13. Global Measles and Rubella (MR) Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Measles and Rubella (MR) Vaccine Market Drivers
Figure 15. Measles and Rubella (MR) Vaccine Market Restraints
Figure 16. Measles and Rubella (MR) Vaccine Market Trends
Figure 17. Global Measles and Rubella (MR) Vaccine Sales Market Share by Manufacturer in 2021
Figure 18. Global Measles and Rubella (MR) Vaccine Revenue Market Share by Manufacturer in 2021
Figure 19. Measles and Rubella (MR) Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Measles and Rubella (MR) Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Measles and Rubella (MR) Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Measles and Rubella (MR) Vaccine Sales Market Share by Region (2017-2028)
Figure 23. Global Measles and Rubella (MR) Vaccine Revenue Market Share by Region (2017-2028)
Figure 24. North America Measles and Rubella (MR) Vaccine Revenue (2017-2028) & (USD Million)
Figure 25. Europe Measles and Rubella (MR) Vaccine Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Measles and Rubella (MR) Vaccine Revenue (2017-2028) & (USD Million)
Figure 27. South America Measles and Rubella (MR) Vaccine Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Measles and Rubella (MR) Vaccine Revenue (2017-2028) & (USD Million)
Figure 29. Global Measles and Rubella (MR) Vaccine Sales Market Share by Type (2017-2028)
Figure 30. Global Measles and Rubella (MR) Vaccine Revenue Market Share by Type (2017-2028)
Figure 31. Global Measles and Rubella (MR) Vaccine Price by Type (2017-2028) & (US$/Unit)
Figure 32. Global Measles and Rubella (MR) Vaccine Sales Market Share by Application (2017-2028)
Figure 33. Global Measles and Rubella (MR) Vaccine Revenue Market Share by Application (2017-2028)
Figure 34. Global Measles and Rubella (MR) Vaccine Price by Application (2017-2028) & (US$/Unit)
Figure 35. North America Measles and Rubella (MR) Vaccine Sales Market Share by Type (2017-2028)
Figure 36. North America Measles and Rubella (MR) Vaccine Sales Market Share by Application (2017-2028)
Figure 37. North America Measles and Rubella (MR) Vaccine Sales Market Share by Country (2017-2028)
Figure 38. North America Measles and Rubella (MR) Vaccine Revenue Market Share by Country (2017-2028)
Figure 39. United States Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Measles and Rubella (MR) Vaccine Sales Market Share by Type (2017-2028)
Figure 43. Europe Measles and Rubella (MR) Vaccine Sales Market Share by Application (2017-2028)
Figure 44. Europe Measles and Rubella (MR) Vaccine Sales Market Share by Country (2017-2028)
Figure 45. Europe Measles and Rubella (MR) Vaccine Revenue Market Share by Country (2017-2028)
Figure 46. Germany Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Measles and Rubella (MR) Vaccine Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Measles and Rubella (MR) Vaccine Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Measles and Rubella (MR) Vaccine Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Measles and Rubella (MR) Vaccine Revenue Market Share by Region (2017-2028)
Figure 55. China Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Measles and Rubella (MR) Vaccine Sales Market Share by Type (2017-2028)
Figure 62. South America Measles and Rubella (MR) Vaccine Sales Market Share by Application (2017-2028)
Figure 63. South America Measles and Rubella (MR) Vaccine Sales Market Share by Country (2017-2028)
Figure 64. South America Measles and Rubella (MR) Vaccine Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Measles and Rubella (MR) Vaccine Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Measles and Rubella (MR) Vaccine Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Measles and Rubella (MR) Vaccine Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Measles and Rubella (MR) Vaccine Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Measles and Rubella (MR) Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Measles and Rubella (MR) Vaccine in 2021
Figure 76. Manufacturing Process Analysis of Measles and Rubella (MR) Vaccine
Figure 77. Measles and Rubella (MR) Vaccine Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のA型肝炎及びB型肝炎用混合ワクチン市場2022年：市場規模予測（～2028年）
  • 世界の肺炎球菌ワクチン多価市場2022年：市場規模予測（～2028年）
  • アジュバント使用インフルエンザワクチンのグローバル市場展望 2023年-2029年：バイアル、充填済み
  • 世界の獣医用ウイルスベクター化ワクチン市場2022年：市場規模予測（～2028年）
  • 世界のIPVワクチン市場2022年：市場規模予測（～2028年）
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19746 )"世界の麻疹・風疹（MR）ワクチン市場2022年：市場規模予測（～2028年）" (英文：Global Measles and Rubella (MR) Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。